← Back to Clinical Trials
Recruiting NCT05734430

NCT05734430 Genetics of Appendix Cancer Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05734430
Status Recruiting
Phase
Sponsor Andreana Holowatyj, PhD, MSCI
Condition Appendix Cancer
Study Type OBSERVATIONAL
Enrollment 700 participants
Start Date 2022-11-11
Primary Completion 2032-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Genetic profilingRetrospective tissue procurement

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 700 participants in total. It began in 2022-11-11 with a primary completion date of 2032-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix/appendiceal cancer who are ages 18+ years.

Eligibility Criteria

Inclusion Criteria: GAP Social * Known diagnosis of appendix cancer in the United States * Mentally and physically able to consent and participate in the study GAP Vanderbilt * Known diagnosis of appendix cancer * Diagnosed by and/or consulting with a physician/clinical provider participating in the GAP Study * Mentally and physically able to consent and participate in the study GAP Parent * Biological parents (mother and/or father) of individuals actively participating in the GAP Study * Residing in the United States * Mentally and physically able to consent and participate in the study Exclusion Criteria: * Women pregnant at the time of consent * Prisoners * Unable to provide informed consent * Unable to read, write, or complete questionnaires in English

Contact & Investigator

Central Contact

GAP Study Coordinator (Rebecca B.)

✉ gapcancerstudy@vumc.org

📞 615-936-8544

Principal Investigator

Andreana N Holowatyj, PhD, MSCI

PRINCIPAL INVESTIGATOR

Vanderbilt-Ingram Cancer Center

Frequently Asked Questions

Who can join the NCT05734430 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Appendix Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05734430 currently recruiting?

Yes, NCT05734430 is actively recruiting participants. Contact the research team at gapcancerstudy@vumc.org for enrollment information.

Where is the NCT05734430 trial being conducted?

This trial is being conducted at Nashville, United States.

Who is sponsoring the NCT05734430 clinical trial?

NCT05734430 is sponsored by Andreana Holowatyj, PhD, MSCI. The principal investigator is Andreana N Holowatyj, PhD, MSCI at Vanderbilt-Ingram Cancer Center. The trial plans to enroll 700 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology